Janus kinase 1 and 1/2 inhibitors for treating drug reaction with eosinophilia and systemic symptoms: a case series
Clinical and Experimental Dermatology · 2026
DOI: 10.1093/ced/llag072 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2026. Verfasst von Weijun Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Hauptthemen laut MEDLINE: Drug Hypersensitivity Syndrome, Janus Kinase Inhibitors, Sulfonamides, Pyrimidines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 9 Literaturangaben. Gefördert von: Natural Science Foundation of Shanghai Municipality.
Abstract (Originalsprache)
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe drug-induced hypersensitivity reaction often requiring prolonged corticosteroid (CS) treatment, yet tapering is challenging due to the risk of relapse. In this retrospective single-centre case series, we evaluated the effectiveness and safety of selective Janus kinase (JAK) inhibitors in facilitating CS tapering in patients with moderate-to-severe refractory DRESS and in ameliorating pruritus. Six patients (median age 35 years, range 9–70, five female) received baricitinib or abrocitinib with CS between July 2023 and June 2024. All achieved rapid clinical improvement, with generalized lesion resolution and a reduction in pruritus by > 3 points on the Worst Itch Numerical Rating Scale. Successful initial CS tapering occurred within 7–12 days. Four patients discontinued CS completely within 28–62 days, while two continued with low-dose CS due to primary autoimmune disease. Serum cytokines, particularly interleukin-5, decreased markedly following JAK inhibition. No severe adverse events occurred, including in patients with pancytopenia or hepatic dysfunction. JAK inhibitors appear to be effective and well-tolerated for promoting CS tapering in patients with refractory DRESS. Larger, controlled studies would be useful to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- Dermatology Hospital of Jiangxi Province, Jiangxi Provincial Clinical Research Center for Skin Diseases, Candidate Branch of National Clinical Research Center for Skin Diseases, Dermatology Institute of Jiangxi Province…
ORCID-Profile: Lihong Chen
Förderung
- Natural Science Foundation of Shanghai Municipality
Zitieren
APA
Liu, W., Wang, Y., Wang, J., Xu, H., Shen, X., Zheng, J., Pan, M., Zhao, X., & Chen, L. (2026). Janus kinase 1 and 1/2 inhibitors for treating drug reaction with eosinophilia and systemic symptoms: a case series. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llag072
Vancouver
Liu W, Wang Y, Wang J, Xu H, Shen X, Zheng J, et al. Janus kinase 1 and 1/2 inhibitors for treating drug reaction with eosinophilia and systemic symptoms: a case series. Clinical and Experimental Dermatology. 2026. doi:10.1093/ced/llag072
BibTeX
@article{Liu2026,
author = {Liu, Weijun and Wang, Youcong and Wang, Jingying and Xu, Han and Shen, Xiaoyan and Zheng, Jie and Pan, Meng and Zhao, Xiaoqing and Chen, Lihong},
title = {Janus kinase 1 and 1/2 inhibitors for treating drug reaction with eosinophilia and systemic symptoms: a case series},
journal = {Clinical and Experimental Dermatology},
year = {2026},
doi = {10.1093/ced/llag072}
}
EUVIMED